MTEC companions with non-public trade, tutorial establishments, authorities companies and different analysis organizations searching for to speed up the event of medical options that forestall and deal with accidents to U.S. navy members. One of many group’s present targets is to establish units or therapies that empower medics to do extra remedy on the level of harm. MTEC’s work with PBG will allow the event of a cell bioreactor that may produce PLTs+ on-demand within the areas the place navy operations are underway, assuaging platelet shortages in battle zones brought on by lack of donor availability, brief platelet shelf life and sterility issues.
“Navy battle zones are sometimes in distant places, that means that medical know-how improvements are paramount to efficient interventions and recoveries,” mentioned Kathy Zolman, MTEC Director of Program Operations. “The work Platelet BioGenesis is doing may assist resolve the shortages that usually have an effect on U.S. navy models. Growing the bioreactor for distant purposes would allow platelets to be out there on-demand, which might make an immense distinction in treating traumatic accidents sustained throughout navy exercise.”
In one other necessary growth, PBG has added Uma Lakshmipathy, Ph.D. and Teresa Foy, Ph.D. to its Scientific Advisory Board (SAB) to assist the continued analysis and growth of platelet-based therapeutic options. Dr. Lakshmipathy is the R&D Director at Thermo Fisher Scientific and is concerned within the growth of reprogramming, engineering and characterization options that assist translation of main and stem cells in direction of novel cell remedy platforms. Dr. Foy is Senior Vice President at Bristol-Myers Squibb (BMS, previously Celgene), main the Thematic Analysis Heart for Immuno-Oncology (IO) and Mobile Remedy (CT). She is accountable for BMS’s IO/CT discovery and early growth pipeline, main a staff that’s advancing novel drug and cell remedy candidates from discovery by way of scientific proof-of-concept.
“Dr. Lakshmipathy and Dr. Foy convey to PBG intensive expertise within the growth of cell therapies, which shall be invaluable as we enter IND-enabling research of our human stem cell-derived, donor-independent platelets in 2020. We stay up for working intently with each of those distinguished trade veterans as we proceed to advance our novel platelet-based cell remedy platform,” mentioned Sam Rasty, Ph.D., the corporate’s President and CEO. “Along with bolstering our SAB with these extremely skilled advisors, the MTEC award supplies us with additional non-dilutive funding and validation of our science and know-how platform. We stay up for partnering with MTEC to advance the event of our cell, automated PLT+ bioreactor.”
About Platelet BioGenesis
Platelet BioGenesis (PBG) has created the one platform that may generate human platelets at scale. The stem cell-derived, on-demand platelets would be the first donor-independent supply of platelets to handle the persistent scarcity worldwide. The corporate can also be creating genetically engineered platelet-based therapeutics, a brand new remedy modality for most cancers and different life-threatening ailments. PBG’s platform is patented and cGMP-compliant. The corporate was spun out of Harvard College and has acquired enterprise funding from Qiming Enterprise Companions USA, Ziff Capital Companions and different traders and obtained grant funding from the Massachusetts Life Sciences Heart, the Nationwide Institutes of Well being and the U.S. Division of Protection. Study extra at www.plateletbiogenesis.com and comply with us on Twitter @plateletbio.